Neue Targets in der Osteoporosetherapie

Schlüsselwörter

Osteoporose - Osteoklastogenese - Zielmoleküle

Keywords

osteoporosis - osteoclastogenesis - target molecules

Literatur

• 1 Bodine P V, Stauffer B, Ponce-de-Leon H. et al . A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation.  Bone. 2009;  44 1063-1068
• 2 Bone H G, McClung M R, Roux C. et al . Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.  J Bone Miner Res. 2010;  25 937-947
• 3 Chantry A D, Heath D, Mulivor A W. et al . Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo.  J Bone Miner Res. 2010;  25 2357-2570
• 4 Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities.  Nat Rev Drug Discov. 2010;  9 804-820
• 5 Eisman J A, Bone H G, Hosking D J. et al . Odanacatib in the treatment of postmenopausal women with low bone mineral density.  J Bone Miner Res. 2011;  26 242-251
• 6 Fajardo R J, Manoharan R K, Pearsall R S. et al . Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).  Bone. 2010;  46 64-71
• 7 Henriksen D B, Alexandersen P, Hartmann B. et al . Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women.  Bone. 2007;  40 723-729
• 8 Henriksen D B, Alexandersen P, Hartmann B. et al . Four-month treatment with GLP-2 significantly increases hip BMD.  Bone. 2009;  45 833-842
• 9 Hofbauer L C, Kuhne C A, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases.  J Musculoskelet Neuronal Interact. 2004;  4 268-725
• 10 Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis.  Curr Osteoporos Rep. 2010;  8 163-167
• 11 Jakob F, Seefried L, Ebert R. Pathophysiologie des Knochenstoffwechsels.  Internist. 2008;  49 1159-1164
• 12 Jakob F. Metabolische Knochenerkrankungen.  Internist. 2007;  48 1101-1107
• 13 Jakob F, Benisch P, Klotz B. et al . Sexualsteroide in der Homöostase des Knochens.  Osteologie/Osteology. 2010;  2 105-110
• 14 Jensen E D, Gopalakrishnan R, Westendorf J J. Regulation of gene expression in osteoblasts.  Biofactors. 2010;  36 25-32
• 15 Kamiya N, Kobayashi T, Mochida Y. et al . Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.  J Bone Miner Res. 2010;  25 200-210
• 16 Kartal-Kaess M, Shore E M. et al . Fibrodysplasia ossificans progressiva (FOP): watch the great toes!.  Eur J Pediatr. 2010;  169 1417-1421
• 17 Kasten P, Beyen I, Bormann D, Luginbuhl R, Ploger F, Richter W. The effect of two point mutations in GDF-5 on ectopic bone formation in a beta-tricalciumphosphate scaffold.  Biomaterials. 2010;  31 3878-3884
• 18 Koncarevic A, Cornwall-Brady M, Pullen A. et al . A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.  Endocrinology. 2010;  151 4289-4300
• 19 Kramer I, Halleux C, Keller H. et al . Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.  Mol Cell Biol. 2010;  30 3071-3085
• 20 Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?.  Trends Endocrinol Metab. 2010;  21 237-244
• 21 Kramer I, Loots G G, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.  J Bone Miner Res. 2010;  25 178-189
• 22 Lewiecki E M. Denosumab – an emerging treatment for postmenopausal osteoporosis.  Expert Opin Biol Ther. 2010;  10 467-476
• 23 Lotinun S, Pearsall R S, Davies M V. et al . A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.  Bone. 2010;  46 1082-1088
• 24 Marie P J. The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis.  Bone. 2010;  46 571-576
• 25 Mason J J, Williams B O. SOST and DKK: Antagonists of LRP family signaling as targets for treating bone disease.  J Osteoporos. 2010;  2010 460 120
• 26 Matsumoto T, Abe M. TGF-beta-related mechanisms of bone destruction in multiple myeloma.  Bone. 2011;  48 129-134
• 27 Moester M J, Papapoulos S E, Lowik C W, van Bezooijen R L. Sclerostin: current knowledge and future perspectives.  Calcif Tissue Int. 2010;  87 99-107
• 28 Nakashima A, Katagiri T, Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts.  J Biol Chem. 2005;  280 37 660-37 668
• 29 Raggatt L J, Partridge N C. Cellular and molecular mechanisms of bone remodeling.  J Biol Chem. 2010;  285 25 103-25 108
• 30 Ralston S H, Uitterlinden A G. Genetics of osteoporosis.  Endocr Rev. 2010;  31 629-662
• 31 Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab.  Nat Rev Drug Discov. 2010;  9 591-592
• 32 Saidak Z, Brazier M, Kamel S, Mentaverri R. Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications.  Mol Pharmacol. 2009;  76 1131-1144
• 33 Saylor P J, Smith M R. Bone health and prostate cancer.  Prostate Cancer Prostatic Dis. 2010;  13 20-27
• 34 Seeman E. Bone modeling and remodeling.  Crit Rev Eukaryot Gene Expr. 2009;  19 219-233
• 35 Shore E M, Kaplan F S. Inherited human diseases of heterotopic bone formation.  Nat Rev Rheumatol. 2010;  6 518-527
• 36 Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling.  Cytokine Growth Factor Rev. 2009;  20 343-355
• 37 Tamura M, Nemoto E, Sato M M, Nakashima A, Shimauchi H. Role of the Wnt signaling pathway in bone and tooth.  Front Biosci (Elite Ed). 2010;  2 1405-1413
• 38 Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis.  Expert Opin Investig Drugs. 2010;  19 995-1005
• 39 Trivedi R, Mithal A, Chattopadhyay N. Anabolics in osteoporosis: the emerging therapeutic tool.  Curr Mol Med. 2010;  10 14-28
• 40 Wagner D O, Sieber C, Bhushan R, Borgermann J H, Graf D, Knaus P. BMPs: from bone to body morphogenetic proteins.  Sci Signal. 2010;  3 mr1
• 41 Walsh D W, Godson C, Brazil D P, Martin F. Extracellular BMP-antagonist regulation in development and disease.  Trends Cell Biol. 2010;  20 244-256
• 42 Walsh J S, Henriksen D B. Feeding and bone.  Arch Biochem Biophys. 2010;  503 11-19
• 43 Yaccoby S. Osteoblastogenesis and tumor growth in myeloma.  Leuk Lymphoma. 2010;  51 213-220
• 44 Jakob F, Benisch P, Bhushan R, Ebert R, Seefried L, Schieker M, Ignatius A. Zelluläre Defekte und Regulationsstörungen bei der Heilung osteoporotischer Frakturen.  Osteologie. 2011;  20 23-28
• 45 Seefried L , Ebert R, Müller-Deubert S. et al . Mechanotransduktion im Alter und bei Osteoporose.  Osteologie. 2010;  19 232-239